Claims
- 1. A pharmaceutical composition useful for treating bacterial infections in mammals including humans which comprises at least a synergistically effective amount of a compound of the formula (II): ##STR9## wherein X is sulphur or oxygen and R is hydrogen or alkyl of 1 to 3 carbon atoms, and an antibacterially effective amount of amoxycillin, a pharmaceutically acceptable salt thereof or an in vivo hydrolyzable ester thereof, in combination with a pharmaceutically acceptable carrier.
- 2. A composition according to claim 1 wherein the ratio of the compound of the formula (II) to amoxycillin, a pharmaceutically acceptable salt thereof or an in vivo hydrolyzable ester thereof, is 3:1 to 1:10.
- 3. A composition according to claim 2 wherein the ration is 1:1 to 1:4.
- 4. A composition according to claim 1 wherein the compound is of the formula (III), (IV), (V), (VI), (VII) or (VIII) ##STR10## wherein R is hydrogen or alkyl of 1 to 3 carbon atoms.
- 5. A composition according to claim 1 wherein R is hydrogen or methyl.
- 6. A composition according to claim 4 wherein R is hydrogen or methyl.
- 7. A composition according to claim 1 wherein the compound is 9-isothiazol-5-methylaminodeoxyclavulanic acid.
- 8. A composition according to claim 1 in oral administration form.
- 9. A composition according to claim 1 in parenteral administration form.
- 10. A composition according to claim 1 in injectible administration form.
- 11. A composition according to claim 1 in a form suitable for infusion.
- 12. A composition according to claim 1 in a form suitable for topical application.
- 13. A method treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof at least a synergistically effective amount of a compound of the formula (II): ##STR11## wherein X is sulphur or oxygen and R is hydrogen or alkyl of 1 to 3 carbon atoms, and an antibacterially effective amount of amoxycillin, a pharmaceutically acceptable salt thereof or an in vivo hydrolyzable ester thereof, in combination with a pharmaceutically acceptable carrier.
- 14. A method according to claim 13 wherein the ratio of compound of the formula (II) to amoxycillin, a pharmaceutically acceptable salt thereof or an in vivo hydrolyzable ester thereof, is 3:1 to 1:10.
- 15. A method according to claim 14 wherein the ratio is 1:1 to 1:4.
- 16. A method according to claim 13 wherein the compound is of the formula (III), (IV), (V), (VI), (VII) or (VIII): ##STR12## wherein R is hydrogen or alkyl of 1 to 3 carbon atoms.
- 17. A method according to claim 13 wherein R is hydrogen or methyl.
- 18. A method according to claim 16 wherein R is hydrogen or methyl.
- 19. A method according to claim 13 wherein the compound is 9-isothiazol-5-yl-methylaminodeoxyclavulanic acid.
- 20. A method according to claim 13 wherein the administration is oral.
- 21. A method according to claim 13 wherein the administration is parenteral.
- 22. A method according to claim 13 wherein the administration is by injection.
- 23. A method according to claim 13 wherein the administration is by infusion.
- 24. A method according to claim 13 wherein the administration is by topical application.
Priority Claims (1)
Number |
Date |
Country |
Kind |
42338/78 |
Oct 1978 |
GBX |
|
CROSS REFERENCE
This is a division of Ser. No. 079,557 filed Sept. 27, 1979, U.S. Pat. No. 4,303,665.
Non-Patent Literature Citations (1)
Entry |
Chemical Abstracts 89: 59890f (1978). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
79557 |
Sep 1979 |
|